[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prodromal-schizophrenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prodromal-schizophrenia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100450226","effects-of-nac-on-symptoms-of-chr-patients-100450226",false,"NCT05142735","Effects of NAC on Symptoms of CHR Patients","Effects of N-acetylcysteine on Psychosis-like Symptoms and a Neurophysiological Biomarker of the Clinical High Risk for Schizophrenia","Inclusion Criteria:\n\n1. meeting Criteria of Psychosis-Risk Syndromes (COPS) criteria on the Structured Interview for Psychosis-Risk Syndromes (SIPS)\n2. capacity to provide informed consent\n3. if female, participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure or have been post-menopausal for at least 1 year prior to screening OR participant is of child-bearing potential and agrees to use a medically approved method of birth control for the duration of the study\n\nExclusion Criteria:\n\n1. meeting criteria for any other DSM-5 diagnosis at the time of the study (except -personality disorder, nicotine use disorder, or other substance use disorder in full remission)\n2. concomitant or past neurological condition\n3. visual impairment which is not corrected to normal by prescription glasses history of reading disability\n4. past antipsychotic treatment at a therapeutic dose\n5. current treatment with a psychotropic medication except antidepressants on which the participants has been on a stable dose for at least 30 days.\n6. pregnancy (as identified on self-report and\u002For rapid urine pregnancy test) or intent to become pregnant according to self-report\n7. breastfeeding or plan to do so\n8. history of kidney stones\n9. current treatment with an antibiotic\n10. current treatment with nitroglycerin\n11. allergy to any ingredients in either the investigational product or placebo product","ALL","16 Years","35 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with \"clinical high-risk\" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals has been shown to help prevent psychosis. Current medications used for CHR symptoms, however, are associated with substantial side effect burden. Therefore, practice guidelines do not recommend current medications as routine treatment for the CHR state, and there is a need to identify new treatments for this condition.\n\nResearch suggests that abnormal brain oxidative stress may contribute to schizophrenia, offering a potential novel treatment target in the CHR state. Oxidative stress is an excess of free radicals, which are generated from normal metabolism and environmental exposures, and can damage cells. Antioxidants in the body normally neutralize free radicals. Antioxidant deficiency could result in excess oxidative stress that damages brain cells, leading to schizophrenia. Recent studies suggest that N-acetylcysteine (NAC), a precursor of the most abundant brain antioxidant, glutathione, may be a safe, well-tolerated treatment for schizophrenia. In light of this, NAC may also reduce symptoms and brain abnormalities in CHR patients.",[27],"Prodromal Schizophrenia",[29,30,31,32,33,34,35],"psychosis","schizophrenia","N-acetylcysteine","prodrome","mismatch negativity","event-related potentials","clinical high risk state","RECRUITING","2026-03-24",{"date":39,"type":40},"2026-03-27","ACTUAL",{"date":42,"type":40},"2023-01-13",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Centre for Addiction and Mental Health","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100443319","phase-2-early-intervention-of-prodromal-schizophrenia-using-an-nmda-enhancer-100443319","NCT05052853","Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer","Inclusion Criteria:\n\n* Individuals meeting Criteria of Prodromal Syndrome (at least one of the following: 1. attenuated positive symptoms; 2. brief intermittent psychotic symptoms; 3. genetic risk and deterioration).\n* Subjects remain symptomatic (scoring at least 20 on the Scale of Prodromal Symptoms \\[SOPS\\] total score) after the 6-week screening phase (which contains the health-promotion program) and before the 12-week drug-trial period.\n* Subjects may be receiving ongoing treatment with antipsychotic medications, or may be medication-free for at least 12 weeks.For the subjects who have already been on such medications, the medications need to be continued for at least 4 weeks before the screening phase and the doses need to be kept unchanged during the study period. For those who have not yet been on such medications, these medications are forbidden during the study period.\n* Subjects agree to participate in the study and provide written informed consent after complete description of the study. For the subject \\\u003C 20 years old, a parent also has to provide written informed consent.\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of intellectual disability, substance (including alcohol) use disorder, schizophrenia, schizophreniform disorder, delusional disorder, schizoaffective disorder, substance\u002Fmedication-induced psychotic disorder, or psychotic disorder due to another medical condition.\n* History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study.\n* Clinically significant laboratory screening tests (including blood routine, biochemical tests)\n* Pregnancy or lactation\n* Inability to follow protocol","13 Years","45 Years",{"count":58,"type":21},48,[60],"PHASE2","Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.",[27],[64,65,66],"Schizophrenia","Prodrome","NMDA","2026-03-21",{"date":37,"type":40},{"date":70,"type":40},"2021-11-01",{"date":72,"type":21},"2026-12",{"name":74,"class":47},"China Medical University Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100449327","targeting-processing-speed-deficits-to-improve-social-functioning-and-lower-psychosis-risk-100449327","NCT05131035","Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk","Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk in Adolescents at Clinical High Risk for Psychosis","SCORES","Inclusion Criteria:\n\n* Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level\n* A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB).\n\nExclusion Criteria:\n\n* Any DSM 5 Schizophrenia-Spectrum diagnosis\n* Non-English speaking\n* Past or current history of a clinically significant central nervous system disorder (e.g., seizure disorder)\n* Estimated IQ\\\u003C70\n* Significant head injury\n* Significant substance abuse\n* Significant visual or auditory impairment.","14 Years","20 Years",{"count":86,"type":21},54,[24],"This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.",[90,27,91],"Psychosis","Prodromal Symptoms",[93,94,95,96,97,98,99],"Clinical High Risk (CHR)","Processing Speed","Social Functioning","Social Impairment","Social Skills","Adolescents","Cognitive Remediation","2025-11-19",{"date":102,"type":40},"2025-11-24",{"date":104,"type":40},"2021-10-28",{"date":106,"type":21},"2026-05-31",{"name":108,"class":47},"Northwell Health"]